The Complex Landscape of Electronic Cigarettes: Trends, Research, and Regulation

A review of recent studies, policy changes, and expert commentary reveals a complex and often contested landscape surrounding electronic cigarettes. Key areas of focus include evolving usage patterns, the role of vaping in smoking cessation, emerging research on potential health risks—particularly cancer—and significant methodological debates within the scientific literature. Regulatory approaches and the persistence of illicit markets further complicate public health efforts.

Usage Trends and Cessation Efforts

Data indicates a shift in nicotine consumption patterns, with vaping becoming increasingly prevalent. In the United Kingdom, the Office for National Statistics reported that in 2026, 5.4 million adults used vapes daily or occasionally, surpassing the 4.9 million adults who smoked cigarettes.

In Australia, survey data shows a rise in experimentation among younger demographics. The 2024 ACT General Health Survey found the number of 16- to 24-year-olds who have tried a vape has almost tripled since 2018. Common reasons cited for starting included curiosity and perceived better taste. Among older smokers in Canberra (aged 45-64), 65.7% reported vaping to help quit tobacco.

Support programs have emerged in response. In Canberra, the Nicotine Knockout program, operated by Anglicare's The Junction Youth Health Service, offers support from nurses and youth workers for people under 25 seeking to quit vaping. Nurse practitioner Diane Bowden reported that while many young people express motivation to quit, some have tried and resumed use previously.

Vaping as a Smoking Cessation Tool

The efficacy of vaping for smoking cessation, particularly for disadvantaged groups, was examined in an Australian clinical trial. The study focused on daily smokers receiving government pensions or allowances. Participants were provided with either vaping products or Nicotine Replacement Therapy (NRT), such as gum or lozenges, alongside a text message support program.

The trial reported that participants in the vaping group were three times more likely to achieve verified continuous abstinence after six months (28.4%) compared to the NRT group (9.6%).

At a seven-month follow-up, 56% of the vaping group continued using the allocated product, compared to 31% in the NRT group. The study noted that adverse events were less frequent in the vaping group, with no significant differences in self-reported respiratory outcomes.

However, the study acknowledged limitations, including that vaping for cessation may lead to longer-term use compared to NRT. In Australia, vaping is a "conditional" recommendation for quitting, typically considered after first-line pharmacotherapies. Challenges to legal access include limited pharmacy stock, a small number of authorized prescribers, and concerns among healthcare professionals about long-term safety and effectiveness.

Health Risk Research and Scientific Debate

Recent research has intensified the debate over vaping's long-term health risks, with a specific focus on cancer.

A review published in the journal Carcinogenesis in March 2026, led by researchers from the University of New South Wales, concluded that "Nicotine-based e-cigarettes are likely to be carcinogenic to humans."

The analysis integrated evidence from animal studies, human biomarker studies, and case reports from 2017 to 2025. It reported observations of DNA damage, oxidative stress, and inflammation in vapers, which are biological changes associated with cancer risk. The review suggested a potential link to lung and oral cancers but stated the exact risk burden remains indeterminate due to a lack of long-term data.

Lead author Adjunct Professor Bernard Stewart described the review as a "definitive determination" of increased cancer risk for vapers compared to non-vapers. Professor Becky Freeman, a public health researcher, noted this study was significant for asserting a likely increased cancer risk for vapers compared to non-vapers, particularly for young people who have never smoked.

The Carcinogenesis review and other studies claiming a vaping-cancer link have faced substantial criticism from other scientists for methodological issues.

• Experts including Professor Peter Hajek and Professor Lion Shahab criticized the review for not comparing cancer risk between vapers and smokers, and for presenting the detection of chemicals at any level as evidence of carcinogenicity without considering dose.
• A separate systematic review published in the Journal of Cancer Policy in 2025, which suggested a possible association between vaping and certain cancers, was retracted in March 2026. The retraction notice cited "substantial concerns regarding the methodological integrity, accuracy, and scientific validity."
• A January 2026 study in Frontiers in Oncology was criticized for a potential "reverse causation" flaw. Critics argued that the study did not establish whether vaping preceded cancer diagnosis, suggesting that smokers who develop symptoms might be more likely to try e-cigarettes.

Dr. Michael Siegel and Dr. Arielle Selya suggested that methodological problems in some studies may stem from a "general bias against tobacco harm reduction." They noted an ethical concern when flawed research is amplified in media, potentially deterring smokers from switching to less harmful alternatives.

Amidst the debate, a recurring point of agreement among many public health experts is the relative risk compared to smoking.

Martin Dockrell, former tobacco evidence lead at the UK's Office for Health Improvement and Disparities, stated that vaping is "considerably less harmful than smoking," attributing this to the absence of combustion and associated toxins like tar and carbon monoxide. Experts consistently state that vaping is not recommended for non-smokers, particularly youth.

Regulation, Accessibility, and the Illicit Market

Regulatory approaches vary and face enforcement challenges. In Australia, since July 2024, vapes can only be legally sold in pharmacies with a prescription to help quit smoking or manage nicotine dependence. Despite this, the illicit market remains widespread.

The ITEC Commissioner’s 2024-25 report estimated that 95.7% of vapes purchased in Australia were illegal, representing an illicit market valued at approximately $1.6 billion.

Individuals report continued ease of access to illegal products. Cameron Owens-Gale, a 28-year-old from Canberra, stated he has not found it difficult to purchase illegal vapes during government crackdowns. Nurse practitioner Diane Bowden reported that for some, the easy accessibility of vapes has led to unconventional outcomes, with one patient taking up smoking cigarettes because they were "a lot harder" to use than having a vape constantly available.

Public health officials call for a multi-faceted approach. Dr. Kerrie Aust advocated for more investment in research, education on harms, and support services. Professor Becky Freeman described Australia's vape laws as "really good" but highlighted a critical lack of enforcement, arguing that full enforcement would make the laws among the best globally. The Australian government has allocated $350 million to enforce measures against the illicit vape and cigarette markets.